HHS Awards $4.9M Toward First US Ibogaine Studies for PTSD

Featured - Most Recent - News
Published: 11/16/2026
ibogaine studies ptsd

The federal government is putting money behind ibogaine, a psychedelic that some Americans already travel abroad to seek as a shortcut through opioid withdrawal.

For anyone researching medical detox, the announcement on November 12 raises a fair question: does this change what safe care looks like right now? It does not, and the details of the funding itself explain why.

What the $4.9 Million Award Covers

Health Secretary Robert F. Kennedy Jr. said his department is awarding up to $4.9 million to prepare for the first U.S. studies of ibogaine for post-traumatic stress disorder, a hard-to-treat condition linked to higher suicide and substance abuse rates among veterans, MedPage Today reported.

The money will not go directly to patient research. It will lay the groundwork needed to manufacture, dose, and design studies of the drug. The government will also receive data and treatment guidance from Beond Inc., a Texas-based company that has treated more than 3,000 patients with ibogaine in Mexico, where the drug is not illegal.

Kennedy said that partnership will dramatically accelerate the clinical trial process and predicted a record drug approval process. Additional funding awards may explore ibogaine’s use for addiction, he said.

Veterans Affairs Secretary Doug Collins joined the announcement and said the effort would focus first on safety and best-in-class research. For veterans living with PTSD, he said, we owe them both urgency and the best science we can produce.

Why Ibogaine Remains Unproven

Ibogaine is made from a shrub native to West Africa. It can cause intense hallucinations, nausea, vomiting, tremors, and sometimes deadly irregular heart rhythms. It is currently illegal, in the same ultra-restrictive class as LSD and ecstasy, and U.S. research on the drug has essentially been frozen for decades because of its restricted status.

The little data available comes mostly from patients who traveled to Mexico or other countries where ibogaine is not heavily regulated. Clinics there typically charge $10,000 to $20,000 for one course of treatment, which often involves monitoring a patient’s heart readings while emergency medical workers stand by.

That price tag, and the fact that cardiac monitoring is the selling point rather than a bonus, tells you most of what you need to know about the current state of the evidence.

The announcement was previewed in April, when President Trump signed an executive order directing agencies to speed up review and research of psychedelics.

Three psychedelic applications are pending at the FDA, including potential medicines made from psilocybin and MDMA, and decisions could come within weeks or months. Because of its safety risks, ibogaine research has moved more slowly.

How This Compares With Proven Detox Care

The contrast with approved care is stark. Medication-assisted treatment for opioid use disorder pairs FDA-approved medications such as buprenorphine, methadone, and naltrexone with counseling, and those medications have established safety records.

They are available now, at a fraction of the cost of an overseas clinic, and they are the standard of care for opioid detox and withdrawal management.

A government funding award is a decision to find out whether a drug works. It is not a finding that it does. Until controlled trials produce evidence and the FDA acts on it, ibogaine remains an unproven treatment with a documented cardiac risk, not an alternative to supervised medical detox programs.

Finding Medical Detox Today

For people weighing detox options now, the practical questions have not changed. Ask what level of medical supervision a program provides, whether clinicians can monitor heart and vital signs around the clock, which medications are used to manage withdrawal, and how the program transitions people into ongoing treatment afterward.

A facility that answers those questions clearly is telling you something about the care it gives. Detox.com’s directory lists medically supervised detox programs across the country that can answer each of those questions.. You can learn more about your treatment options by calling 800-996-6135 .

Written by: Nikki Wisher

BA

Nikki Wisher is an Atlanta-based content writer with over a decade of experience specializing in health and wellness. While she spends most of her days writing about various aspects of health, from addiction recovery to fitness to skin care, she also writes content in many other areas like photography, beauty, and marketing. Her passion project is her inclusive running blog, forallrunners.com.

View Profile

Reviewed by: Eric Owens

Eric has a passion for content creation, whether it’s writing articles or making YouTube videos. He appreciates the power of storytelling to inform an audience about the information they need to know. In addition to writing, he also spends his time traveling and discovering new restaurants.

View Profile

Get Help Today Phone icon 800-779-4314